Publications by authors named "Holly B Krasa"

Claim this Profile
E
Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis.
Michael Lioudis, Xiaolei Zhou, Eric Davenport, Sasikiran Nunna, Holly B Krasa

BMC Nephrol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing What Matters to People Affected by Alzheimer's Disease: A Quantitative Analysis.
Brett Hauber, Russ Paulsen, Holly B Krasa, George Vradenburg, Meryl Comer

Neurol Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease.
Dana B DiBenedetti, Heather Menne, Russ Paulsen, Holly B Krasa, George Vradenburg

Neurol Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney Disease.
Dorothee Oberdhan, Jason C Cole, Mark J Atkinson, Holly B Krasa, Sara N Davison

Clin J Am Soc Nephrol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD.
Xiaolei Zhou, Eric Davenport, John Ouyang, Molly E Hoke, Diana Garbinsky, Holly B Krasa

Kidney Int Rep· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing what matters most to patients with or at risk for Alzheimer's and care partners: a qualitative study evaluating symptoms, impacts, and outcomes.
Dana B DiBenedetti, Christina Slota, Samantha L Wronski, George Vradenburg, Meryl Comer, Holly B Krasa

Alzheimers Res Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review.
Pablo E Pergola, Roberto Pecoits-Filho, Wolfgang C Winkelmayer, Bruce Spinowitz, Samuel Rochette, Holly B Krasa

Pharmacoecon Open· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.
Bruce Spinowitz, Roberto Pecoits-Filho, Wolfgang C Winkelmayer, Pablo E Pergola, Samuel Rochette, Holly B Krasa

J Med Econ· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument.
Dorothee Oberdhan, Jason C Cole, Holly B Krasa, Rebecca Cheng, Frank S Czerwiec

Am J Kidney Dis· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of autosomal dominant polycystic kidney disease in the European Union.
Cynthia J Willey, Jaime D Blais, Anthony K Hall, Holly B Krasa, Andrew J Makin

Nephrol Dial Transplant· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
Ron T Gansevoort, Esther Meijer, Arlene B Chapman, Frank S Czerwiec, Olivier Devuyst, Holly B Krasa

Nephrol Dial Transplant· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of tolerable treatment options for patients with schizophrenia.
Leslie Citrome, Anna Eramo, Clement Francois, Ruth Duffy, Susan N Legacy, Holly B Krasa

Neuropsychiatr Dis Treat· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
Ronald D Perrone, Jon Neville, Arlene B Chapman, Berenice Y Gitomer, Dana C Miskulin, Holly B Krasa

Am J Kidney Dis· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Wendy E Boertien, Esther Meijer, Paul E de Jong, Gert J ter Horst, Remco J Renken, Holly B Krasa

Am J Kidney Dis· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
Wendy E Boertien, Esther Meijer, Paul E de Jong, Stephan J L Bakker, Frank S Czerwiec, Holly B Krasa

Kidney Int· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
Paul J Hauptman, John Burnett, Mihai Gheorghiade, Liliana Grinfeld, Marvin A Konstam, Holly B Krasa

J Card Fail· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Vicente E Torres, Arlene B Chapman, Olivier Devuyst, Ron T Gansevoort, Jared J Grantham, Holly B Krasa

N Engl J Med· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
Muthiah Vaduganathan, Mihai Gheorghiade, Peter S Pang, Marvin A Konstam, Faiez Zannad, Holly B Krasa

J Cardiovasc Med (Hagerstown)· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
Eiji Higashihara, Vicente E Torres, Arlene B Chapman, Jared J Grantham, Kyongtae Bae, Holly B Krasa

Clin J Am Soc Nephrol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
Maria V Irazabal, Vicente E Torres, Marie C Hogan, James Glockner, Bernard F King, Holly B Krasa

Kidney Int· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Vicente E Torres, Esther Meijer, Kyongtae T Bae, Arlene B Chapman, Olivier Devuyst, Holly B Krasa

Am J Kidney Dis· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.
Philip L Cyr, Katherine A Slawsky, Natalia Olchanski, Holly B Krasa, Thomas F Goss

Am J Health Syst Pharm· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of tolvaptan on dyspnoea relief from the EVEREST trials.
Peter S Pang, Marvin A Konstam, Holly B Krasa, Karl Swedberg, Faiez Zannad

Eur Heart J· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction.
Norman C Wang, Aldo P Maggioni, Marvin A Konstam, Faiez Zannad, Holly B Krasa

JAMA· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis